ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1537

Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1520

Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1447

Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1493

Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1432

Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1443

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1454

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1456

Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1560

Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1587

Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1289

Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus

(1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0959

Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score

(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1644

Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis

(1633–1649) ARP Posters II: ARP Epidemiology & Public Health

10:30AM-12:30PM: Abstract Number: 0909

Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1543

Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].